Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuxi AppTec CoWUXIF +3.02%81 Net Cash per Share is $0.68 as of Jun. 2026. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $16.84 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 62 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks worse than 80.65% on this metric.
The historical rank and industry rank for Wuxi AppTec Co's Net Cash per Share or its related term are showing as below:
WUXIF'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 14.49 Med: 47.49 Max: 526.48
Current: 34.68
During the past 12 years, the highest Price-to-Net-Cash Ratio of Wuxi AppTec Co was 526.48. The lowest was 14.49. And the median was 47.49.
WUXIF's Price-to-Net-Cash is ranked worse than 80.65% of 62
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.42
vs WUXIF: 34.68
Wuxi AppTec Co (OTCPK:WUXIF) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Wuxi AppTec Co Net Cash per Share Related Terms
Wuxi AppTec Co Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, NTRA: Net Cash per Share Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Price-to-Net-Cash vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Wuxi AppTec Co's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a Net Cash per Share of $0.68 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #50 out of 62 companies in the Medical Diagnostics & Research industry, placing it in the top 80.6%.
Is Wuxi AppTec Co's Net Cash per Share too high?
Wuxi AppTec Co's current Net Cash per Share is $0.68. The Medical Diagnostics & Research industry median Net Cash per Share is 9.42. Wuxi AppTec Co's value of $0.68 is 92.8% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #50 out of 62 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Net Cash per Share compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #50 out of 62 companies for Net Cash per Share. This places Wuxi AppTec Co in the lower half of its industry. The industry median Net Cash per Share is 9.42. Wuxi AppTec Co's value of $0.68 is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Diagnostics & Research company?
The median Net Cash per Share among Medical Diagnostics & Research companies is 9.42, based on 62 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Net Cash per Share of $0.68 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Net Cash per Share is 9.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Net Cash per Share is $0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $16.84, compared to a current price of $26.70 — trading 58.6% above its estimated fair value. The current Net Cash per Share is $0.68 and 92.8% below the Medical Diagnostics & Research industry median of 9.42. Wuxi AppTec Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Net Cash per Share is $0.68 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $26.70 is trading 58.6% above its estimated GF Value™ of $16.84.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Net Cash per Share: $0.68
GF Value™: $16.84 vs. price of $26.70 (58.6% above fair value)
Industry Position: 92.8% below the Medical Diagnostics & Research median (#50 of 62)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
